Hepatocellular Carcinoma

17 competing products in clinical development for Hepatocellular Carcinoma.

Pipeline by Phase

Phase 13

Phase 1/23

Phase 25

Phase 2/31

Phase 35

All Products (17)

Product	Company	Stage	Status	Hype
Atezolizumab + Bevacizumab + Tiragolumab	Chugai Pharmaceutical	Phase 3	Active	44
Nivolumab	Ono Pharmaceutical	Phase 3	Active	44
Irinotecan + Sonidegib + Sorafenib	Sun Pharmaceutical	Phase 2	Recruiting	42
Lenvatinib	Eisai	Phase 2	Recruiting	42
Ramucirumab + Placebo	Eli Lilly	Phase 3	Completed	40
Tivantinib + Placebo	Daiichi Sankyo	Phase 3	Completed	40
Nivolumab + Sorafenib	Ono Pharmaceutical	Phase 3	Completed	40
Lenvatinib Pill	Eisai	Phase 2	Active	39
Lenvatinib	Eisai	Phase 2	Active	39
Sorafenib + Sorafenib	Eisai	Phase 1/2	Completed	32
Lenvatinib	Eisai	Phase 1/2	Completed	32
Nivolumab + Sorafenib + Ipilimumab + Cabozantinib	Ono Pharmaceutical	Phase 1/2	Completed	32
camrelizumab& apatinib	Sun Pharmaceutical	Phase 2	UNKNOWN	31
Menatetrenone + Menatetrenone + Placebo	Eisai	Phase 2/3	Terminated	30
GC33(RO5137382) + Sorafenib	Chugai Pharmaceutical	Phase 1	Completed	29
Enzalutamide + Enzalutamide with Sorafenib	Astellas Pharma	Phase 1	Completed	29
lenvatinib + pembrolizumab (200 mg)	Eisai	Phase 1	Completed	29